Why an Alaskan’s love affair with Reno, perfumed streets and all, makes perfect sense
Print article It typically happens in February. The sun has been so distant that it’s way too little and way too late by the time it finally starts to fill the days. I find myself over Alaska in a profound way, and sorely missing one place in particular: the desert. I’m originally from Massachusetts. Shouldn’t I be missing the gentle rolling forests, lakes and creeks? Shouldn’t the Citgo sign be flashing in my mind’s eye like a siren’s song, calling me home? Fenway?
(1)
DEFINING CLEAR DEVELOPMENT PATHWAY FOR NEXT GENERATION OF PSYCHEDELIC MEDICINES TO TREAT ADDICTION
Toronto, Ontario (Newsfile Corp. - April 27, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicines to treat Addiction, announced today the initiation of a new chemical entity (NCE) development program to strengthen Awakn s pipeline for the treatment of a broad range of addictions. The Company has also announced the appointment of Evotec as NCE research partner and the selection of Prof. David Nutt, one of the world s leading experts on addiction, as program lead.
This announcement follows Awakn s March 2021 acquisition of a significant body of proprietary research from Equasy Enterprises, including details of newly discovered actions of MDMA (Equasy Acquisition).